[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wugen, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100555646",false,"NCT06514794","A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed\u002FRefractory Cell Acute Lymphoblastic Leukemia\u002FLymphoblastic Lymphoma (T-RRex)","Key Inclusion Criteria:\n\n* Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse\u002Frefractory or MRD positive\n* Age: Lower age limit of ≥ 6 months; adequate organ function\n* Eastern Cooperative Oncology Group (ECOG)\u002FKarnofsky Performance Status 0 or 1\u002F70 and above at Screening.\n\nKey Exclusion Criteria:\n\n* Prior treatment with any anti-CD7 therapy.\n* Patients with decompensated hemolytic anemia.\n* Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable.","ALL","1 Year",{"count":18,"type":19},125,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed\u002FRefractory (R\u002FR) T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u002FLymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response",[25,26],"T-cell Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma",[28],"CAR-T Therapy","RECRUITING","2026-05-09",{"date":32,"type":33},"2026-05-12","ACTUAL",{"date":35,"type":33},"2025-01-31",{"date":37,"type":19},"2028-12-30",{"name":39,"class":40},"Wugen, Inc.","INDUSTRY",15,""]